Global Archives – Treatment Action Group

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

August 1, 2022
Dorrit Walsh

We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available

August 1, 2022
Dorrit Walsh

Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.

1 / 4 / 6 x 2024

July 25, 2022
Dorrit Walsh

Inspired by the legacy of Dr. Paul Farmer, the 1 / 4 / 6 x 24 Campaign calls for the "staff, stuff, space, systems and support" necessary to make groundbreaking short-course TB prevention and treatment regimens accessible to all who need them as a human right by the end of 2024.

Cover Of Pipeline Report 2022. Black Cover With Grey Type And Decorative Bright Green Lines

2022 Pipeline Report

July 24, 2022
Dorrit Walsh

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

Cover That Reads TB CAB 10-Year Anniversary Evaluation Report 2011-2021, March 2022, By Andrea DeLuca, Also Has A Black And Whilte Photo Montage Of People Engaged In Meetings And Demonstrations

TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast

July 18, 2022
Dorrit Walsh

In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.

Research Toward a Cure Trials

July 15, 2022
Dorrit Walsh

A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

Research in Action Awards 2022

July 8, 2022
Dorrit Walsh

On Monday, November 14, 2022 TAG’s 2022 Research in Action Awards (RIAA) will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world.

Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline

July 1, 2022
Dorrit Walsh

A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.

Roundtable on Access to Multi-disease Molecular Diagnostics

June 23, 2022
Dorrit Walsh

On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…

Cover Of TAG's Annual Report. Reads: 2021 TAG Annual Report, Progress In The Fight For Better Treatment, Prevention, A Vaccine, And A Cure For HIV, Tuberculosis, And Hepatitis C Virus

2021 Annual Report

June 3, 2022
Dorrit Walsh

This year we celebrate the unending dedication and accomplishments of TAG’s staff. They persevered through the challenges of an ongoing pandemic in 2021 to find new ways to carry out our work.